|Year : 2018 | Volume
| Issue : 1 | Page : 84-89
Preablation neutrophil-to-lymphocyte ratio as an independent prognostic factor in locally advanced hepatocellular carcinoma patients following radiofrequency ablation
Wei Tan1, Wenkui Sun2, Xia Li1, Lei Zhao1, Chun Wang1, Aihua Zang1, Xiangchong Kong1
1 Department of Ultrasound, Qingdao Municipal Hospital, The Affiliated Hospital of Qingdao University, Qindao, China
2 Department of Ultrasound, Weifang People's Hospital, Weifang, Shandong, China
|Date of Web Publication||8-Mar-2018|
Dr. Xia Li
Department of Ultrasound, Qingdao Municipal Hospital, The Affiliated Hospital of Qingdao University, 1# Jiaozhou Road, Qindao
Source of Support: None, Conflict of Interest: None
Background and Aims: Neutrophil-to-lymphocyte ratio (NLR), as an inflammation-based marker, plays critical roles in hepatocellular carcinoma (HCC). This study was aimed to investigate the prognostic value of preablation NLR in locally advanced HCC patients following radiofrequency ablation (RFA) and to determine an optimal cutoff value for NLR.
Materials and Methods: From September 2008 to May 2017, 402 locally advanced HCC patients treated with RFA were retrospectively evaluated. Several prognostic factors including NLR was assessed with univariate and multivariate analysis. The optimal cutoff value of NLR was determined with a maximally selected log-rank test. Other prognostic factors influenced the overall survival (OS) were also evaluated.
Results: Based on the univariate analysis of 16 prognostic factors for OS, the type of hepatitis, a-fetoprotein (AFP), NLR, alanine aminotransferase, aspartate aminotransferase, and serum albumin were identified as independent prognostic factors; and based on multivariate analysis of 6 prognostic factors for OS, AFP, and NLR were identified (P < 0.05). A NLR of 2.2 was determined to be the optimal cutoff value (area under the curve = 0.855, P < 0.001). In a comparison between the high NLR group and the low NLR group, there was a difference of 7 months in the median OS (24 vs. 31 months, P < 0.001).
Conclusions: Preablation NLR was a valuable predictor in locally advanced HCC patients treated with RFA. NLR ≥2.2 indicated a poor prognosis. These findings suggested that preablation NLR may be a convenient, easily-obtained, low cost, and reliable biomarker with prognostic potential for HCC patients.
Keywords: Locally advanced hepatocellular carcinoma, neutrophil-to-lymphocyte, radiofrequency ablation
|How to cite this article:|
Tan W, Sun W, Li X, Zhao L, Wang C, Zang A, Kong X. Preablation neutrophil-to-lymphocyte ratio as an independent prognostic factor in locally advanced hepatocellular carcinoma patients following radiofrequency ablation. J Can Res Ther 2018;14:84-9
|How to cite this URL:|
Tan W, Sun W, Li X, Zhao L, Wang C, Zang A, Kong X. Preablation neutrophil-to-lymphocyte ratio as an independent prognostic factor in locally advanced hepatocellular carcinoma patients following radiofrequency ablation. J Can Res Ther [serial online] 2018 [cited 2021 Jun 24];14:84-9. Available from: https://www.cancerjournal.net/text.asp?2018/14/1/84/226766
| > Introduction|| |
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer-associated mortality worldwide. It indicated the poor prognosis of HCC., With the improvement of imaging diagnosis, the incidence of locally advanced HCC has been increasing. The standard treatments for unresectable locally advanced HCC have been transarterial chemoembolization (TACE), radiofrequency ablation (RFA), microwave ablation, laser ablation (LA), and cryoablation., RFA has become one main modality of locoregional therapy because of its effectiveness and safety for small HCC (D ≤5.0 cm), with a 3-year survival rate of 62%–77%, a low treatment complication rate of 8%–9%, and a low treatment mortality rate of 0%–0.5%. Recently, increasing evidence has shown that the presence of systemic inflammation was correlated with poorer survival in some cancer patients.,,,,, Several studies have shown that the pretherapy neutrophil-to-lymphocyte ratio (NLR) was an independent predictor for prognosis in HCC patients treated with liver transplantation, surgical resection, TACE, thermal ablation, and sorafenib.,,, The NLR (neutrophil count to the lymphocyte count) has been a useful and readily available indicator in clinic that reflected the potential balance between neutrophil-associated pro-tumor inflammation and lymphocyte-dependent antitumor immune function.,,, The elevated NLR may represent a trend toward increased protumor inflammation and decreased antitumor immune function. However, the optimal cutoff value of NLR was approximately ranged from 1.0 to 5.0, which was too wide to be applied in clinic.,, In addition, to the best of our knowledge, seldom study was performed on the prognostic role of NLR in locally advanced HCC patients following RFA.
In this study, we aimed to investigate the preablation NLR as a prognostic factor in locally advanced HCC patients treated with RFA and to determine the optimal cut-off value for determining NLR. In addition, the correlations between NLR and patients' clinicopathological features were also assessed. Furthermore, a simple preablation prognostic system would be established, which may assist in the selection of patients who would benefit most from RFA.
| > Materials and Methods|| |
This research was approved by the Medical Ethics Committee of our hospitals. Written informed consent was obtained from all the participating patients.
From September 2008 to May 2017, 402 locally advanced HCC patients (299 male and 103 female, aged 18–92 years, mean ± standard deviation: 51.7 ± 10.6 years) were enrolled in this study, with a total of 1098 HCC nodules detected by either conventional ultrasound (US) or contrast-enhanced US (CEUS)/computed tomography (CT)/magnetic resonance imaging (MRI). All patients received curative ablation. The mean diameter of lesions in our study was 2.9 ± 1.0 cm (ranged from 1.0 to 5.0 cm). The previous treatment of patients included surgical (83 cases, 20.6%), TACE (96 cases, 23.9%), and ablation (radiofrequency, microwave, cryoablation, and LA) (223 cases, 55.5%). The types of virus infections included hepatitis B virus (HBV) (262 patients, 65.2%), hepatitis C virus (HCV) (64 patients, 15.9%), HBV + HCV (10 patients, 2.5%), and without virus infection (66 patients, 16.4%). Liver cirrhosis was observed in 313 patients (77.9%). The differentiation degree was classified by high level (51 cases, 12.7%), middle level (334 cases, 83.1%), and low level (17 cases, 4.2%). The Child-Pugh score was evaluated as A (382 cases, 95.0%) and B (20 cases, 5.0%). The NLR is the ratio of the neutrophil count to the lymphocyte count. The final diagnosis of HCC was determined by pathological examination of surgical specimens or biopsy specimens.
The inclusion criteria were listed as follows: (1) Nonresectable locally advanced HCC or patient refused to receive surgery; (2) age of ≥18 years; (3) Eastern Cooperative Oncology Group performance status of 0 or 1; (4) single HCC lesion ≤5 cm; (5) more than two nodules, with a maximum diameter ≤3 cm; (6) absence of portal vein thrombosis or extrahepatic metastases; (7) without serious blood coagulation disorders; (8) a follow-up of at least 3 months after RFA treatment. The exclusion criteria were listed as follows: (1) severe cardiopulmonary disease; (2) serious renal function failure; (3) severe liver function failure, such as uncontrollable ascites, hepatic encephalopathy, and serious esophageal gastric varices; and (4) active or severe infection which may affect preablation NLR.
All treatments were performed after hospitalization. An enhanced CT or MRI scan of the abdomen and pelvis were performed within 1 month before the treatment for all patients, as well as the electrocardiogram. Serum laboratory tests were performed in 1 week before the treatment. CEUS was regularly performed to confirm tumor coverage and tumor number before RFA.
Real-time US systems, LOGIC-E9 (GE Healthcare, Milwaukee, WI, USA) were applied for scanning with 3.5–5.0 MHz convex probes for ablation procedures. Before RFA, an US/CEUS-guided biopsy was performed with an automatic biopsy gun and a 18G cutting needle under local anesthesia with 1% lidocaine. During each biopsy, 2–3 punctures were performed. Subsequently, the antennas were percutaneously inserted into the tumor and placed in the desired location under the guidance of US or CEUS.
After the patients were consciously sedated and locally anesthetized, RFA was performed percutaneously by US guidance. Tumors were ablated through multiple overlapping insertions (2–4) by single electrode with a 1.0- or 3.5-cm exposed tip (ValleyLab, Burlington, MA). Emission time was lasted for 12 or 30 min by a 200W generator set. Complete ablation was defined as the ablation zone coverage a 0.5–1.0 cm width margin of the normal liver parenchyma surrounding the tumor if the ablation zone could be enlarged. Or else, a shaped ablation was performed. To completely ablate the tumor close to the bile duct, gallbladder, or bowel, ethanol was injected into the marginal tumor tissue through a 21G percutaneous transhepatic cholangiography needle during the ablation. When the hyperecho overlapped in the whole lesion, the electrode was withdrawn. The needle tracks were routinely cauterized to avoid bleeding and tumor seeding.,
The enhanced images were obtained at 7-day after RFA and the complete ablation was defined as no-enhancement in any area of the lesion. Subsequently, patients were followed with repeat US and CT/MRI every 2–3 months during the 1st year and every 4–6 months in the following years. The period of follow-up was ranged from 3 to 60 months. Residual tumor, local progression, and new tumors were retreated if another RFA session could be tolerated by the patient.
The data were analyzed with SPSS for Windows (Version 21.0, SPSS Inc, Chicago, IL, USA). Variables statistically significant in the univariate analysis were involved into a multivariable Cox proportional hazards analysis. The prognostic value of preablation NLR was assessed taking into account of the effects from confounding factors. The optimal cutoff value of NLR was determined by receiver operating characteristic (ROC) curve analysis. Independent Chi-square tests were applied to compare categorical variables. Continuous variables were compared by unpaired t-tests. The overall survival (OS) curves were analyzed by the Kaplan-Meier method and compared with the log-rank test. P < 0.05 indicated statistically significant.
| > Results|| |
Correlation between neutrophil-lymphocyte ratio and overall survival following radiofrequency ablation by univariate and multivariate analysis in locally advanced hepatocellular carcinoma patients
To determine whether preablative NLR was correlated with prognosis after RFA in locally advanced HCC patients, both univariate and multivariate analyses were performed. On univariate analysis of 16 prognostic factors for OS, the type of hepatitis, a-fetoprotein (AFP), NLR, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum albumin (ALB) were identified as independent prognostic factors (P< 0.05). Then, the six independent prognostic factors were further evaluated with multivariate Cox proportional hazard model analysis. AFP and NLR were identified as independent prognostic factors (P< 0.05) [Table 1]. The results suggested that NLR was an independent prognostic factors for OS in locally advanced HCC patients following RFA.
|Table 1: Univariate and multivariate analysis of clinical factors in relation to survival of locally advanced hepatocellular carcinoma patients|
Click here to view
Selection of the optimal cutoff value of neutrophil-lymphocyte ratio for predicting overall survival after locally advanced hepatocellular carcinoma patients receiving radiofrequency ablation
To analyze preablative NLR value for predicting OS after locally advanced HCC patients receiving RFA, a time-dependent ROC curve was performed. An NLR of 2.2 was considered the optimal cutoff value to predict the prognosis after RFA (area under the ROC was 0.855, P < 0.001) [Figure 1]. Therefore, NLR was determined as a risk factor for prognosis, with a cutoff value of 2.2. All patients were divided into either a low (NLR <2.2) NLR group (n = 152) or a high (NLR ≥2.2) NLR group (n = 250). The results indicated that high NLR was observed in 62.2% (250/402) patients in locally advanced HCC, which may be inclined to a poor prognosis [Figure 2].
|Figure 1: Receiver operating curves analysis for neutrophil-lymphocyte ratio predicating prognosis in locally advanced hepatocellular carcinoma patients following radiofrequency ablation neutrophil-lymphocyte ratio = 2.2 was considered to be evaluated (area under the receiver operating characteristic = 0.855; P < 0.001)|
Click here to view
|Figure 2: Comparison of overall survival in the low (neutrophil-lymphocyte ratio <2.2) and high (neutrophil-lymphocyte ratio ≥2.2) neutrophil-lymphocyte ratio groups. The overall survival was significantly higher in the low neutrophil-lymphocyte ratio group than in the high neutrophil-lymphocyte ratio group in locally advanced hepatocellular carcinoma patients following radiofrequency ablation (P < 0.001)|
Click here to view
Comparisons of the overall survival between low- and high-neutrophil-lymphocyte ratio groups of locally advanced hepatocellular carcinoma
To compare the difference of OS between the low- and high-NLR groups in locally advanced HCC, the differences of basic clinical parameters were first eliminated between the two groups. A total of 15 clinical parameters were compared between the low NLR and high NLR groups [Table 2], [Table 3], [Table 4]. No significantly difference was found in gender, age, type of hepatitis, differentiation, Child-Pugh, cirrhosis, number of tumor, size of tumor, and prothrombin time between the two groups. While, significant difference was detected in pretreatments, AFP, cholinesterase (CHE), AST, ALT, and ALB. The results suggested that high NLR was negatively associated with these 6 clinical factors.
|Table 2: Comparison of clinical parameters of locally advanced hepatocellular carcinoma patients between the low- and high-neutrophil-lymphocyte ratio groups|
Click here to view
|Table 3: Comparison of clinical parameters of locally advanced hepatocellular carcinoma patients between the low and high NLR groups|
Click here to view
|Table 4: Comparison of clinical parameters of locally advanced hepatocellular carcinoma patients between the low and high NLR groups (continued)|
Click here to view
During the follow-up period (median: 27 months), a comparison between the high NLR group and the low NLR group was performed with a significant difference. Seven months difference in the median OS was detected (24 months in high NLR group versus 31 in low NLR group, P < 0.001). The results suggested that high NLR (≥2.2) indicated a poor prognosis in locally advanced HCC patients.
| > Discussion|| |
It reported that the development of cancers including HCC was closely related with the balance of inflammation and immunity status, and the liver was an immune organ itself. HCC commonly occurs on the background of chronic liver disease, which induces chronic inflammation and impaired immunity. NLR was a useful, easy available clinic indicator that reflected systemic inflammatory response in some cancers.,, A high level of neutrophil was related to the release of chemokines and interleukins, which promoted tumor growth and metastasis in HCC. Lymphocytes was related to T lymphocyte-mediated antitumor response, and a low level of lymphocyte reflected a weak lymphocyte-mediated immune response to tumor. Previous studies have shown that a higher NLR was correlated with adverse survival outcomes in patients with various solid tumors.,,,
RFA has emerged as one of the standard treatments for HCC patients according to the Barcelona-clinic liver cancer group., This technique was designed to induce tumor destruction by delivering a high frequency alternating current through an active needle-electrode introduced into the neoplastic tissue. The resultant movement generated frictional heating which leads to cell death by means of coagulative necrosis. Cellular death would be instantaneously observed at temperatures above 60°C. Increasing number of studies demonstrated that RFA treatment released tumor antigen to prime the immune system and to induce antitumor immunity.,, The present retrospective study with a relatively large cohort of locally advanced HCC patients suggested that high preablation NLR was associated with poor survival, confirmed by both univariate and multivariate analysis. The results suggested that NLR and AFP were independent prognostic factors for predicting OS in locally advanced HCC patients receiving RFA. AFP was a useful factor for predicting prognosis in many studies which have been verified. However, NLR has not been analyzed as a representative index of immunity status in locally advance HCC patients. In this study, by ROC analysis, the optimal cutoff value of NLR was verified as 2.2. Moreover, 62.2% locally advanced HCC patients with high NLR may indicate a poor immunity status. The ratio was similar to that of in the prior report in recurrent HCC patients after thermal ablation.
In the comparison of OS between the low and high NLR groups in locally advanced HCC, pretreatments, AFP, CHE, AST, AL, and ALB were verified as potential influence factors. However, in univariate and multivariate analysis, these factors were not considered as influence factors for prognosis. Thus, after eliminating the differences of basic clinical parameters between the two groups, the prognosis was differenced significantly in HCC patients in low and high NLR groups. In locally advanced HCC patients, prolonged survival time of 7 months was observed. This result may not only assist clinician in predicting HCC patients' survival before and after ablation but also reminding the clinician to perform timely adjuvant treatment to improve the prognosis of patients with preablation NLR of ≥2.2.
The results of present study should be interpreted with caution considering several limitations. First, this study was limited by the retrospective nature of the analysis and based on patients at seldom institutions. Second, C-reactive protein as another important inflammation index was not analyzed in this study. In addition, the mechanism of the relationship between NLR and prognosis in locally advanced HCC patients was not examined and analyzed. Therefore, multicenter prospective studies would be conducted to confirm and further perfect the findings demonstrated in this study.
| > Conclusions|| |
The results of this study suggest that preablation NLR was a valuable predictor in locally advanced HCC patients treated with RFA. NLR cutoff of ≥2.2 indicated a poor prognosis, and this value may remind clinician to perform timely adjuvant treatment to improve the prognosis for patients with preablation high NLR. These findings suggested that preablation NLR may be a convenient, easily-obtained, low cost, and reliable biomarker with prognostic potential for locally advanced HCC patients.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| > References|| |
Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA, et al.
International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer 2016;139:1534-45.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A, et al.
Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al.
Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: Analysis of prognostic factors. J Hepatol 2013;58:89-97.
Chok KS. Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol 2015;7:1142-8.
Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, et al.
Early-stage hepatocellular carcinoma in patients with cirrhosis: Long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961-7.
Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: A review and look into the future. Ann Surg 2003;237:171-9.
Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al.
Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 2012;19:217-24.
Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011;104:1288-95.
Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, et al.
Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. Med Oncol 2013;30:721.
Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al.
Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013;109:416-21.
Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M, et al.
The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215-20.
Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother 2013;62:471-9.
da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, et al.
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol 2014;31:264.
Dan J, Zhang Y, Peng Z, Huang J, Gao H, Xu L, et al.
Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS One 2013;8:e58184.
Li X, Han Z, Cheng Z, Yu J, Liu S, Yu X, et al.
Preoperative neutrophil-to-lymphocyte ratio is a predictor of recurrence following thermal ablation for recurrent hepatocellular carcinoma: A retrospective analysis. PLoS One 2014;9:e110546.
Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, et al.
Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013;58:58-64.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
Wu Y, Zhao Q, Peng C, Sun L, Li XF, Kuang DM, et al.
Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. J Pathol 2011;225:438-47.
Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010;120:1151-64.
Nind AP, Nairn RC, Rolland JM, Guli EP, Hughes ES. Lymphocyte anergy in patients with carcinoma. Br J Cancer 1973;28:108-17.
Qi X, Li J, Deng H, Li H, Su C, Guo X, et al.
Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Oncotarget 2016;7:45283-301.
Son SH, Park EY, Park HH, Kay CS, Jang HS. Pre-radiotherapy neutrophil-to-lymphocyte ratio as an independent prognostic factor in patients with locally advanced hepatocellular carcinoma treated with radiotherapy. Oncotarget 2017;8:16964-71.
Halazun KJ, Hardy MA, Rana AA, Woodland DC 4th
, Luyten EJ, Mahadev S, et al.
Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009;250:141-51.
Xu X, Chen W, Zhang L, Miao R, Zhou Y, Wan Y, et al.
Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin Med J (Engl) 2014;127:4204-9.
Yang W, Wu H, Zhang ZY, Lee JC, Wang S, Wang YJ, et al.
Long-term outcome of percutaneous radiofrequency ablation in recurrent hepatocellular carcinoma after liver transplantation. Int J Hyperthermia 2018;34:68-76.
Liang P, Yu J, Lu MD, Dong BW, Yu XL, Zhou XD, et al.
Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy. World J Gastroenterol 2013;19:5430-8.
Yu J, Yu XL, Han ZY, Cheng ZG, Liu FY, Zhai HY, et al.
Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: A phase III randomised controlled trial. Gut 2017;66:1172-3.
Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. Clin Cancer Res 2009;15:425-30.
Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003;6:283-7.
Li X, Chen ZH, Ma XK, Chen J, Wu DH, Lin Q, et al.
Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol 2014;35:11057-63.
Tsai PL, Su WJ, Leung WH, Lai CT, Liu CK. Neutrophil-lymphocyte ratio and CEA level as prognostic and predictive factors in colorectal cancer: A systematic review and meta-analysis. J Cancer Res Ther 2016;12:582-9.
Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, et al.
Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011;54:948-55.
Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, et al.
FOXP3+regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;13:902-11.
Liu PH, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, et al.
When to perform surgical resection or radiofrequency ablation for early hepatocellular carcinoma? A nomogram-guided treatment strategy. Medicine (Baltimore) 2015;94:e1808.
Qi X, Shao H, Zhang J, Sun Z, Ni Y, Xu K, et al.
Radiopharmaceutical study on iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis. Radiol Med 2015;120:213-21.
McGahan JP, Brock JM, Tesluk H, Gu WZ, Schneider P, Browning PD, et al.
Hepatic ablation with use of radio-frequency electrocautery in the animal model. J Vasc Interv Radiol 1992;3:291-7.
Li G, Staveley-O'Carroll KF, Kimchi ET. Potential of radiofrequency ablation in combination with immunotherapy in the treatment of hepatocellular carcinoma. J Clin Trials 2016;6. pii: 257.
Behm B, Di Fazio P, Michl P, Neureiter D, Kemmerling R, Hahn EG, et al.
Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. Gut 2016;65:134-43.
Wissniowski TT, Hänsler J, Neureiter D, Frieser M, Schaber S, Esslinger B, et al.
Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 2003;63:6496-500.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3], [Table 4]